Why Is CELCUITY INC (CELC) Stock Up Today?

Celticity Inc shares rose 7.84% to $66.39 on Tuesday. The primary driver was a wave of positive analyst actions, including a new initiation from Cantor Fitzgerald and a price target increase from TD Cowen.

What Happened

Cantor Fitzgerald initiated coverage on Celcuity with an overweight rating and a $140 price target. The firm noted a credible path to multi-billion-dollar peak sales for the company. TD Cowen also raised its price target on the stock to $145, reiterating a buy recommendation. Needham maintained its buy rating but lowered its price target to $134. These actions followed the announcement that Celcuity’s drug, REVTORPYK, is commercially available in the United States for people with hormone receptor-positive conditions.

What The Data Shows

The stock opened at $61.93, a 0.6% gap up from the prior close of $61.56. It reached a session high of $66.65 at 9:50 AM ET and a low of $61.05 at 8:35 AM ET. Volume stood at 0.4 million shares, which is 0.3 times the three-month daily average. Celcuity has a market capitalization of $2.9 billion and is currently unprofitable, with a trailing twelve-month EPS of -4.32. The stock has a beta of 0.11 and a 52-week range of $53.54 to $151.02. Over the last eight sessions, the stock had declined 6.7% from $65.85 to $61.43. The company printed 12 fresh 52-week highs on October 22, 2026.

What To Watch

Investors will monitor the breadth of analyst coverage following the recent initiations and upgrades. The stock’s reaction to the commercial launch of REVTORPYK will also be a key factor in near-term price action.